Barclays maintains Huntsman at Equal-Weight, raises price target to $11 from $10

Barclays kept Huntsman at Equal-Weight, raising its price target to $11 from $10, a 10% increase. This implies 15.2% upside from the Nov 3 close of $9.55. Other recent analyst targets range from $9 to $10.

Original reporting
Published Nov 4, 2026, 6:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 6:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays maintains Huntsman at Equal-Weight, raises price target to $11 from $10 — source image
Decision brief

The 30-second read

$HUNBullishMed
01

Why it matters

The new target implies a 15% upside from the recent close, which may prompt short‑term buying.

02

Market read

A modest analyst upgrade that could generate short‑term price movement in Huntsman.

03

What to watch

Potential supply‑chain constraints or commodity price volatility not addressed in the note.

Relevance 5/10Novelty 5/10Timing: intraday today

Background

Barclays' analyst note updates its valuation for Huntsman Corp.

Company-level read

Ticker impact

$HUNBullishMedium confidence
Context

Barclays raised its price target on Huntsman to $11 from $10, a 10% increase.

Expected impact

potential upward pressure as investors price in the higher target

Evidence & confidence

A fresh price‑target raise is new information that can attract buying interest, but the magnitude is modest.

Market effects

May lift sentiment in the specialty chemicals sector.

Limited to U.S. investors tracking chemical stocks.

Low; impact confined to Huntsman and peers.

Counterpoint

The target raise could be premature if recent earnings miss expectations.

Key entities

  • Barclays

    Equity research firm issuing the price‑target upgrade.

  • Huntsman Corp

    Specialty chemicals manufacturer.

Related articles

$HUNMed

KeyBanc raises Huntsman stock price target on merger synergies

KeyBanc raised its price target for Huntsman (NYSE:HUN) to $13, citing merger synergies with OLN and better-than-expected Q3 results. The stock trades at $9.45, with a Fair Value of $13.16. Huntsman reported mixed Q3 earnings, missing EPS estimates but exceeding revenue forecasts. Jefferies initiated coverage with a Buy rating and $12 target. The company faces rising input costs but aims for $100M EBITDA improvement in 2026.

$HUNMed

Huntsman Q3 Earnings Call Highlights

Huntsman (HUN) reported Q3 earnings, noting seasonal slowing and higher raw-material costs in North American MDI markets. The company expects 2027 industry MDI growth to be flat to 2% and sees growth opportunities in advanced materials and automotive applications. Huntsman generated $82M in free cash flow in Q3 and anticipates substantial cash inflow in Q4. Europe remains challenging due to high energy costs, while China's market shows stability.

$HUNMed

Huntsman Corp (HUN) (Q3 2026) Earnings Call Highlights: $100 Million EBITDA Boost

Huntsman Corp (HUN) reported a $100M EBITDA boost in Q3 2026, with CEO Peter Huntsman expressing confidence in meeting $300M synergy targets from the Olin merger. He discussed market positioning, cost management, and growth expectations, including GDP-plus growth in Advanced Materials through 2027. The company expects to cover its dividend and capex with operating cash flow, despite minimal cash flow in the first nine months.

$HUNMedAI 8/10

Huntsman: Q3 Earnings Snapshot

Huntsman Corp. (HUN) reported a Q3 loss of $18M, or 10 cents per share, missing analyst expectations of 7 cents per share. Adjusted earnings were 4 cents per share. Revenue was $1.72B, exceeding forecasts of $1.6B.